Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Baxter International Inc. (BAX)

Surgical & Medical Instruments & Apparatus

https://www.baxter.com

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.

ONE BAXTER PKWY, DF2-1W
DEERFIELD, IL

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/15/1961

Market Cap

18,460,790,930

Shares Outstanding

507,320,000

Weighted SO

507,323,509

Total Employees

N/A

Upcoming Earnings

N/A

Beta

0.5740

Last Div

1.1600

Range

31.01-44.01

Chg

0.4550

Avg Vol

5001262

Mkt Cap

18460790930

Exch

NYSE

Country

US

Phone

224 948 2000

DCF Diff

-57.9656

DCF

94.0781

Div Yield

0.0321

P/S

1.2310

EV Multiple

14.9591

P/FV

2.4145

Div Yield %

3.2057

P/E

7.4533

PEG

1.0465

Payout

0.2379

Current Ratio

1.4016

Quick Ratio

0.9147

Cash Ratio

0.3417

DSO

65.5184

DIO

112.6473

Op Cycle

178.1658

DPO

47.2100

CCC

130.9558

Gross Margin

0.3551

Op Margin

0.0637

Pretax Margin

-0.0050

Net Margin

0.1651

Eff Tax Rate

-0.9733

ROA

0.0941

ROE

0.3064

ROCE

0.0474

NI/EBT

-33.0133

EBT/EBIT

-0.0785

EBIT/Rev

0.0637

Debt Ratio

0.4904

D/E

1.6883

LT Debt/Cap

0.5772

Total Debt/Cap

0.6280

Int Coverage

2.2079

CF/Debt

0.0910

Equity Multi

3.4426

Rec Turnover

5.5710

Pay Turnover

7.7314

Inv Turnover

3.2402

FA Turnover

3.0998

Asset Turnover

0.5700

OCF/Share

2.3020

FCF/Share

1.0157

Cash/Share

4.1078

OCF/Sales

0.0783

FCF/OCF

0.4412

CF Coverage

0.0910

ST Coverage

0.4757

CapEx Coverage

1.7896

Div&CapEx Cov

0.9430

P/BV

2.4145

P/B

2.4145

P/S

1.2310

P/E

7.4533

P/FCF

35.6386

P/OCF

15.7192

P/CF

15.7192

PEG

1.0465

P/S

1.2310

EV Multiple

14.9591

P/FV

2.4145

DPS

1.1600

Latest Headlines (EST)

GlobeNewswire Inc. Mar 20, 04:00 Medical Composites Market is Forecasted to Reach US$ 845 Million in 2030, Says Stratview Research GlobeNewswire Inc. Dec 05, 00:30 Hemodialysis and Peritoneal Dialysis Market to Surpass Valuation of USD 142.97 Billion by 2031 | SkyQuest Technology Benzinga Dec 05, 00:30 Hemodialysis and Peritoneal Dialysis Market to Surpass Valuation of USD 142.97 Billion by 2031 | SkyQuest Technology GlobeNewswire Inc. Sep 02, 00:30 Multifunctional Attributes of Pediatric Nutrition Market: Future Market Insights, Inc. Benzinga Dec 12, 08:48 Don't Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts Benzinga Dec 04, 12:00 Morgan Stanley Maintains Equal-Weight Rating for Baxter Intl: Here's What You Need To Know Seeking Alpha Nov 27, 00:43 Dividend Champion, Contender, And Challenger Highlights: Week Of November 26 Zacks Investment Research Nov 02, 22:30 Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Zacks Investment Research Nov 02, 22:30 Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Zacks Investment Research Nov 02, 22:30 Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Investing.com Oct 31, 12:15 Earnings Coming in Better-Than-Expected, but Stocks Still Getting Punished

Revenue Product Segmentation